Median Technologies (ALMDT) today announces the appointment of Jean-Christophe Montigny as Chief Financial Officer. He will be a member of Median’s executive committee.

Median Technologies (ALMDT) today announces strong business growth for the first half of 2021 (unaudited figures): 71% increase in half-year revenue to €10.1m from €5.9m in H1 2020, a record half-year revenue growth – Order backlog at €52.5m as of June 30th, 2021- Cash and cash equivalents expected at €36.9m

These two appointments follow a series of first successful achievements for iBiopsy® in 2020 and early 2021. Median prepares to launch its iBiopsy® product development plan, including regulatory aspects, define its go-to-market strategy then expand its iBiopsy® operations globally.

Median is building a cloud based end-to-end approach performing both localization and discrimination of malignant and benign lung lesions. The company plans to demonstrate the potential of deep learning models to increase the accuracy, consistency and adoption of lung cancer screening worldwide. First results for a proof of concept on a cohort of 1,800 patients are expected in H2, 2021.

The research collaboration agreement covers a joint clinical retrospective study on liver fibrosis severity in Non-Alcoholic Steato-Hepatitis (NASH) patients. The collaboration will enable Median to work on a large NASH patient cohort to lead the validation of its iBiopsy®’s AI technology, applied to liver fibrosis characterization. The Liver Center at UC San Diego is a world-renowned university and healthcare center for liver diseases, with a focus on Non-Alcoholic Fatty Liver Disease (NAFLD) & NASH